Related Experiment Video
Updated: May 20, 2026

09:38
Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
Postmortem Pittsburgh Compound B (PiB) binding increases with Alzheimer's disease progression
Tina L Beckett1, Robin L Webb, Dana M Niedowicz
1Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY 40536-0230, USA.
Journal of Alzheimer'S Disease : JAD
|July 7, 2012
Summary
Pittsburgh Compound B (PiB) imaging effectively tracks Alzheimer's disease (AD) progression by correlating with amyloid-beta (Aβ) pathology in affected brain regions. This supports PiB as a valuable diagnostic tool for early AD detection.
Failed At:
2026-06-19T13:43:33.001286+00:00
Related Concept Videos
Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...